Michael Toporek - 14 Feb 2025 Form 3 Insider Report for Capstone Holding Corp. (CAPS)

Reporting relationship: Director
Issuer ticker: CAPS
Reported as of: 14 Feb 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 24 Jul 2026, 16:27:32 UTC
Prior SEC filing: 12 Dec 2024
Next SEC filing: 24 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael Toporek

Key filing fact

Michael Toporek filed Form 3 for Capstone Holding Corp. (CAPS) on 24 Jul 2026.

Key facts

This page summarizes Michael Toporek's Form 3 filing for Capstone Holding Corp. (CAPS).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Jul 2026, 16:27.

Change

Previous filing in this sequence was filed on 12 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001243628 Primary reporting owner

TOPOREK MICHAEL

Relationship: Director
Address: 18400 76TH AVENUE, TINLEY PARK
Signature: /s/ Michael Toporek
Signature date: 24 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAPS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 121,774
Date: 14 Feb 2025
Ownership: See footnote
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CAPS holding Derivative

Common Stock Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Feb 2025
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 6,322
Exercise price: $75.00
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of 121,774 shares controlled by Michael Toporek, through his control of BP Peptides, LLC. Brookstone Acquisition Partners XXI Corporation owns 81% of BP Peptides, LLC. Mr. Toporek owns approximately 30% of Brookstone Acquisition Partners XXI Corporation.

Footnote F2

Includes a warrant to purchase up to 6,322 shares of Common Stock issued to Brookstone Partners IAC, Inc., the investment manager of BP Peptides, LLC which is controlled by Matthew Lipman and Michael Toporek.